Press Releases

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Therapeutic Solutions International Releases “IsoStilbene” Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of “Universal Cancer Antigen” into StemVacs Dendritic Cell Platform

Therapeutic Solutions International Announces Licensing of Additional Technologies to Pan American Cancer Treatment Center

Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

Therapeutic Solutions International Releases “DermalStilbene” a Topical Formulation of Pterostilbene

Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant NanoStilbene

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers

Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board

Therapeutic Solutions International, Inc. strengthens the TSOI Scientific Advisory Board with the Appointment of Pablo A. Guzman, MD

Therapeutic Solutions International, Inc. files new patent for the Synergistic Inhibition of Glioma Using Pterostilbene

Therapeutic Solutions International Returns to Fully Reporting Status with SEC

Therapeutic Solutions Subsidiary, SandBox Dental Labs, files 510(k) with FDA

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Therapeutic Solutions International Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Blood Derived Innate Immune System Stimulator

Therapeutic Solutions International Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants

Therapeutic Solutions International Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc.

Therapeutic Solutions International’s Subsidiary OmniBiome, Inc. Announces First Oral Microbiome Therapy for Periodontal Disease

Therapeutic Solutions International’s Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

Therapeutic Solutions International Announces Filing of new Immunotherapy Patent and Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene

Therapeutic Solutions International Announces New Liposomal Products

For Older Press Releases Visit MarketWired